Restylane / Bausch Health 
Welcome,         Profile    Billing    Logout  
 7 Diseases   5 Trials   5 Trials   192 News 


123»
  • ||||||||||  Restylane / Bausch Health
    Preclinical, Journal:  Comparative in-vitro degradation of hyaluronic acids exposed to different hyaluronidase enzymes. (Pubmed Central) -  Feb 3, 2025   
    Four commercially available HA were used: Lyft (Lt; Restylane, Galderma, Sweden), Voluma (Vol; Allergan, AbbVie, USA), UltraDeep (UDe; Rennova, Innovapharma, Brazil), and Subskin (Skn; Perfectha, Sinclair, France)...Furthermore, differences among HSE formulations do not appear to significantly impact HA degradation, while the mixing movement of HSE and HA seems to influence the degradation rate. These findings may help guide clinical decisions regarding the use of hyaluronidase in managing HA filler complications or adjustments.
  • ||||||||||  Restylane / Bausch Health, epinephrine / Generic mfg.
    Journal:  Inflammatory Reactions to Laryngeal Injection of Hyaluronic Acid Derivatives. (Pubmed Central) -  Jan 11, 2025   
    Inflammatory reactions to hyaluronic acid derivatives used in injection laryngoplasty are rare but represent significant patient morbidity and can be managed with anti-inflammatory and airway stabilizing measures. Patients should be counseled appropriately regarding the risks of injection laryngoplasty with hyaluronic acid derivatives.
  • ||||||||||  Restylane / Bausch Health
    Enrollment closed:  Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing (clinicaltrials.gov) -  Aug 29, 2023   
    P=N/A,  N=225, Active, not recruiting, 
    More clinical practice is needed to verify the connection between the cohesion of Hyalumatrix and the clinical performance. Recruiting --> Active, not recruiting
  • ||||||||||  Restylane / Bausch Health
    Enrollment closed, Trial completion date, Trial primary completion date:  Safety and Effectiveness of Restylane (clinicaltrials.gov) -  Aug 16, 2023   
    P=N/A,  N=50, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Feb 2025 | Trial primary completion date: Aug 2023 --> Jan 2025
  • ||||||||||  Enrollment closed:  BILUS: [Trial of device that is not approved or cleared by the U.S. FDA] (clinicaltrials.gov) -  Jul 20, 2023   
    P=N/A,  N=220, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Feb 2025 | Trial primary completion date: Aug 2023 --> Jan 2025 Recruiting --> Active, not recruiting
  • ||||||||||  Restylane / Bausch Health
    Retrospective data, Review, Journal, Adverse events:  Adverse Events Reported From Hyaluronic Acid Dermal Filler Injections to the Facial Region: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jun 1, 2023   
    There was no significant difference in the proportion of individuals experiencing pain, erythema, bruising, tenderness, itching, or skin discoloration at the nasolabial fold site versus the other sites. The study highlights the prevalence of common AEs that can result from HA dermal fillers like Juvederm or Restylane, thus emphasizing the importance of healthcare professionals explaining the risk and benefits to patients.
  • ||||||||||  Restylane / Bausch Health
    Trial completion, Trial completion date:  Safety and Effectiveness of STYLAGE (clinicaltrials.gov) -  Apr 19, 2023   
    P=N/A,  N=390, Completed, 
    Different doses of collagen at different injection rates have the same safety profile. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2023
  • ||||||||||  Restylane / Bausch Health
    Trial completion date, Trial primary completion date:  RES: Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers (clinicaltrials.gov) -  Mar 22, 2023   
    P=N/A,  N=15, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
  • ||||||||||  Restylane / Bausch Health
    Trial completion date:  Safety and Effectiveness of STYLAGE (clinicaltrials.gov) -  Dec 2, 2022   
    P=N/A,  N=390, Active, not recruiting, 
    The authors' in vitro analyses support clinical recommendations stating that in the case of a vascular filler incident, HYAL should be applied early and at significant doses ("Time is skin!"). Trial completion date: May 2023 --> Dec 2022
  • ||||||||||  Restylane / Bausch Health
    Enrollment open:  Safety and Effectiveness of Restylane (clinicaltrials.gov) -  Jul 18, 2022   
    P=N/A,  N=50, Recruiting, 
    NA. Not yet recruiting --> Recruiting
  • ||||||||||  Restylane / Bausch Health
    New trial:  Safety and Effectiveness of Restylane (clinicaltrials.gov) -  Apr 25, 2022   
    P=N/A,  N=50, Not yet recruiting, 
  • ||||||||||  Restylane / Bausch Health
    Journal:  MRI imaging versus histologic volumetric estimation of residual injection laryngoplasty material. (Pubmed Central) -  Apr 19, 2022   
    Following left recurrent laryngeal nerve transection, rabbit vocal cords were injected with jellyfish collagen, Cymetra®, or Restylane®...MRI imaging demonstrates good reliability and similar estimates of volume to histologically estimated measurements of residual injection laryngoplasty material at time points clinically relevant for future injection laryngoplasty experiments. NA.
  • ||||||||||  Restylane / Bausch Health
    Enrollment closed:  Safety and Effectiveness of STYLAGE (clinicaltrials.gov) -  Jan 4, 2022   
    P=N/A,  N=390, Active, not recruiting, 
    Moreover, compared with the superficial injection, the deep injection provided slight midface lifting and improved facial aesthetics. Recruiting --> Active, not recruiting
  • ||||||||||  Restylane / Bausch Health
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  HALR: Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease (clinicaltrials.gov) -  Oct 4, 2021   
    P4,  N=2, Terminated, 
    The results of this study raise questions regarding the efficacy of hyaluronidase in degrading cross-linked HAFs. N=40 --> 2 | Trial completion date: Mar 2021 --> Sep 2021 | Recruiting --> Terminated | Trial primary completion date: Mar 2021 --> Sep 2021; recruitment challenges
  • ||||||||||  Restylane / Bausch Health
    Enrollment open:  Safety and Effectiveness of STYLAGE (clinicaltrials.gov) -  Jul 27, 2021   
    P=N/A,  N=388, Recruiting, 
    MX-JC + ADSC showed low grade immunity while the XHA showed greater myocyte loss compared to the other groups. Not yet recruiting --> Recruiting